24.02.2023 - WTX-330 is designed as systemically delivered, conditionally activated IL-12 therapy Phase 1 Study of WTX-330 is intended to evaluate the safety, tolerability, and clinical activity of WTX-330 in Patients with Advanced or Metastatic Solid Tumors . Seite 1
01.09.2022 - - First clinical candidate of a new class of systemically delivered conditionally activated INDUKINE therapeutics developed by Werewolf - WTX-124 is designed to target delivery of a highly potent, wild-type IL-2 cytokine to the tumor . Seite 1
06.06.2022 - CAMBRIDGE, Mass., June 06, 2022 (GLOBE NEWSWIRE) - Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to .
24.03.2022 - -Closed upsized IPO in May 2021 raising $120 million in gross proceeds- -Announced clinical trial collaboration with Merck for WTX-124 INDUKINETM program- -Reported positive preclinical data at SITC demonstrating the potential to drive targeted .